相似文献
1
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980.
2
Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43.
3
Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x.
4
[Biological therapy as treatment of inflammatory bowel diseases].
Ugeskr Laeger. 2008 Jun 9;170(24):2152-6.
5
Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Curr Opin Gastroenterol. 2009 Jul;25(4):323-8. doi: 10.1097/MOG.0b013e32832c073a.
6
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Gut. 2010 Oct;59(10):1363-8. doi: 10.1136/gut.2010.212712. Epub 2010 Jun 29.
7
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
8
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2.
9
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S202-8. doi: 10.1016/S0399-8320(09)73155-0.
10
Update on idiopathic colitides.
Curr Opin Gastroenterol. 2013 Jan;29(1):60-5. doi: 10.1097/MOG.0b013e32835abc93.
引用本文的文献
1
Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis.
Heliyon. 2024 Feb 8;10(4):e25357. doi: 10.1016/j.heliyon.2024.e25357. eCollection 2024 Feb 29.
2
Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?
Frontline Gastroenterol. 2011 Jul;2(3):144-150. doi: 10.1136/fg.2010.003566. Epub 2011 Apr 4.
3
Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
PLoS One. 2015 Dec 15;10(12):e0144900. doi: 10.1371/journal.pone.0144900. eCollection 2015.
4
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
Mediators Inflamm. 2015;2015:493012. doi: 10.1155/2015/493012. Epub 2015 Aug 3.
5
Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Clin Pharmacokinet. 2016 Mar;55(3):257-74. doi: 10.1007/s40262-015-0316-9.
6
Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses.
Pharmacol Res Perspect. 2015 Mar;3(2):e00118. doi: 10.1002/prp2.118. Epub 2015 Feb 10.
7
State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.
Nat Rev Gastroenterol Hepatol. 2013 Jul;10(7):413-22. doi: 10.1038/nrgastro.2013.69. Epub 2013 May 7.
8
Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis.
Int J Colorectal Dis. 2013 Aug;28(8):1049-55. doi: 10.1007/s00384-013-1654-4. Epub 2013 Feb 3.
9
The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.
Gastroenterol Hepatol (N Y). 2008 Mar;4(3):197-9.
10
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.
Can J Gastroenterol. 2009 Mar;23(3):185-202. doi: 10.1155/2009/201430.
本文引用的文献
1
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7. doi: 10.1097/MPG.0b013e31802f6424.
2
Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):165-7. doi: 10.1097/MPG.0b013e318031d61a.
3
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Gastroenterology. 2007 Jan;132(1):52-65. doi: 10.1053/j.gastro.2006.11.041. Epub 2006 Nov 29.
4
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Gut. 2007 Sep;56(9):1226-31. doi: 10.1136/gut.2006.099978. Epub 2007 Jan 17.
5
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77. doi: 10.1158/1055-9965.EPI-06-0300.
6
Review article: thiopurines in inflammatory bowel disease.
Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29. doi: 10.1111/j.1365-2036.2006.02980.x.
7
Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2006 Jul 15;24(2):331-42. doi: 10.1111/j.1365-2036.2006.02977.x.
8
Safety issues with biological therapies for inflammatory bowel disease.
Curr Opin Gastroenterol. 2006 Jul;22(4):370-6. doi: 10.1097/01.mog.0000231810.87901.e8.
9
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
10
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. doi: 10.1016/j.cgh.2006.03.002.
Zotero 插件